Search

Memorial Sloan Kettering Cancer Center (MSK) today celebrated the opening of a $1.5 billion state-of-the-art cancer treatment facility with government officials, members of the Boards of Overseers and Managers, and staff. Opening for patient care next month, the 750,000-square-foot building is the institution’s — and the city’s — largest freestanding cancer care facility. The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center is a healing community dedicated to patient-centered care, made possible by a landmark donation and a pioneering vision that signifies a new era of cancer care.

… Tuesday, December 10, 2019 Memorial Sloan Kettering Cancer Center (MSK) today celebrated the opening of a $1.5 billion state-of-the-art cancer treatment facility with government officials, members of the Boards of Overseers and Managers, and staff. Opening for patient care next month, the 750,000-square-foot

Learn how MSK works to keep people with cancer heart healthy.

… Thursday, February 13, 2020 Summary People with cancer are at a significantly higher risk of heart disease during and after treatment. The issue has taken on more importance because people are living longer after a cancer diagnosis. Cancer is challenging enough on its own. Now, a recent study published

New MSK research supported the approval of a new treatment for ER-positive, HER2-negative advanced breast cancer; suggests a new strategy for overcoming resistance to Akt inhibitors in patients with PTEN-mutated prostate cancers; provides new understanding of B cell lymphomas that could lead to new treatments; examines using ChatGPT to help capture patient-reported outcomes; and developed the first customizable, scalable model for palliative care training for emergency departments.

… Thursday, February 13, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) supported the approval of a new treatment for ER-positive, HER2-negative advanced breast cancer; suggests a new strategy for overcoming resistance to Akt inhibitors in patients with PTEN -mutated prostate cancers

After treatment for rectal cancer, Roxanne Joseph is back to enjoying an active life with her husband, Rory, and their two children. Recent research by MSK computational biologist Henry Walch is shedding light on why colorectal cancer has been more difficult to treat in many Black people.

… Saturday, July 1, 2023 By Jim Stallard At first, Roxanne Joseph thought she was just hitting the gym weights too hard. The Brooklyn police officer was in top physical condition at age 41 and felt great. But after noticing blood in her stool, she remembered her uncle’s colorectal cancer diagnosis four

Después de recibir tratamiento para el cáncer de recto, Roxanne Joseph ha vuelto a disfrutar de una vida activa junto a su marido, Rory, y sus dos hijos. Una investigación reciente realizada por Henry Walch, biólogo computacional del MSK, está arrojando luz sobre por qué el cáncer colorrectal ha sido más difícil de tratar en muchas personas de raza negra.

… Saturday, July 1, 2023 Por Jim Stallard Al principio, Roxanne Joseph pensó que estaba exagerando con las pesas en el gimnasio. La oficial de policía de Brooklyn estaba en óptimas condiciones físicas a los 41 años y se sentía muy bien. Pero después de notar sangre en sus heces, recordó el diagnóstico

A new immunotherapy approach involves engineering CAR T cells to produce proteins that treat lymphoma.

… Thursday, September 29, 2016 Summary Researchers have modified CAR T cells to produce a protein called HVEM that could treat lymphoma . When injected, the cells naturally zero in on the location of the cancer cells and churn out HVEM continuously for several days. This new immunotherapy approach could

Meet Tiffany Traina, a breast medical oncologist and the Vice Chair of the Department of Medicine at Memorial Sloan Kettering.

… Friday, April 2, 2021 Summary Tiffany A. Traina, MD , is Vice Chair of the Department of Medicine and has been a medical oncologist on the Breast Medicine Service since 2006. She is also the Section Head of the Triple Negative Breast Cancer Clinical Research Program in which she works to develop new

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval of new drugs and new indications in multiple myeloma clinical trials.

… Thursday, August 8, 2024 A Q&A with MSK Experts  MSK played a central role in the U.S. Food and Drug Administration (FDA)  Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval

Meet Lisa DeAngelis, MSK's new Physician-in-Chief. She discusses her upbringing, her early career at MSK, and her top priorities as physician-in-chief.

… Thursday, January 2, 2020 Summary Lisa DeAngelis, the new Physician-in-Chief, has deep roots at MSK. After more than 30 years at Memorial Sloan Kettering, Lisa DeAngelis still gets up at 6 a.m. , goes to the gym if she’s feeling ambitious, and walks to and from work with her husband, Peter Okin, a cardiology

Thank you to our donor community. Your commitment to supporting Memorial Sloan Kettering Cancer Center (MSK) is essential to advancing our mission.

… Friday, April 1, 2022 Fundraising Events at MSK Cycle for Survival’s 2022 Season and 2021 Allocations Cycle for Survival is the movement to beat rare cancers. The 2022 season featured stationary-cycling events in 15 outdoor locations across the country in April and May. Instructors from Equinox, Cycle